Todd has been a healthcare CFO, consultant, advisor, and investor for over 25 years.  Most recently, he was a Partner at HealthQuest Capital for 7 years. Todd retired from HealthQuest in 2023 when the firm was managing approximately $2b in investments; he remains an Executive-in-Residence for the fund as needed.

Before HealthQuest, he helped build multiple successful companies as a Chief Financial Officer, raising more than $500M in equity and debt, including two IPOs, and driving exits totaling more than $ 3.5 B. He served as CFO and Treasurer of ZS Pharma (IPO in 2014; sold to AstraZeneca in 2015). Todd was also the CFO and head of business development for Sarcode, which developed Xiidra, the first dry-eye pharmaceutical to be approved (2016) for both signs and symptoms of dry eye (sold to Shire in 2013; now marketed by Bausch & Lomb). Before Sarcode, he was the CFO of Sirion Therapeutics. This ophthalmic company received approval for two products (Durezol and Virgan) and was sold to Alcon in 2010 after spinning out Virgan to Bausch & Lomb. Between 2015 and 2021, he served as a financial advisor (and acting CFO) to Femasys (NASDAQ:FEMY), a medtech company developing and selling devices for women’s health. 

Earlier in his career, Todd worked in healthcare venture investing for Quintiles (now IQVIA) and as a consultant at SRI International. He also cofounded two companies: Centice, a spectroscopy platform spinout of Duke University, and TLC Pharma, a specialty pharmaceutical business.

He continues to advise startup healthcare companies and holds several independent Board positions. He is an executive-in-residence for Moffitt Cancer Center’s Office of Innovation and Industry Alliances and a board member at Moffitt. Todd holds bachelor’s degrees in finance and accounting from Miami (Ohio) University, which he attended on a baseball scholarship, and an MBA from Duke University.